Positive Survival Results from Apatorsen Phase II Trial in Metastatic Bladder Cancer November 29, 2016Vol.39 No.10
New Evidence-Based Guideline on HER2 Testing for Patients with Gastric Cancer November 29, 2016Vol.39 No.10
Nektar Phase II Study: Anti-tumor activity in 7/18 evaluable patients with solid tumors November 29, 2016Vol.39 No.10
Drugs & Targets FDA Approves New Indications for Darzalex, Keytruda, Opdivo November 29, 2016Vol.39 No.10
Phase III Keytruda Study Shows Better OS vs. Chemo for Advanced Urothelial Cancer November 29, 2016Vol.39 No.10
Binimetinib plus encorafenib produces PFS improvement vs vemurafenib monotherapy November 29, 2016Vol.39 No.10
Drugs & Targets Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa October 20, 2016Vol.39 No.09
